The development and validation of the Norfolk QOL-DN, a new measure of patients' perception of the effects of diabetes and diabetic neuropathy
- PMID: 15929681
- DOI: 10.1089/dia.2005.7.497
The development and validation of the Norfolk QOL-DN, a new measure of patients' perception of the effects of diabetes and diabetic neuropathy
Abstract
Background: This study was designed to develop and validate a patient-reported outcomes measure, sensitive to the different features of diabetic neuropathy (DN)-small fiber, large fiber, and autonomic nerve function.
Methods: The review of 1,000 structured patient interviews guided the development of 28 items pertaining specifically to the symptoms and impact of large fiber, small fiber, and autonomic nerve function. These items, in addition to 14 generic health status items and five general information items formed the 47-item Norfolk Quality of Life Questionnaire-Diabetic Neuropathy (QOL-DN). Items were grouped according to small fiber, large fiber, and autonomic nerve function, symptoms, and activities of daily living (ADL). Scores in individual domains were aggregated to provide a total score. Item groupings were tested for their ability to distinguish between the effects of specific nerve fiber deficits in 262 subjects-81 healthy controls (C), 86 controls with diabetes (DC), and 95 patients with DN-using one-way analysis of variance (ANOVA). Internal consistency was estimated using Cronbach's alpha coefficient. Test-retest reliability over a 4-6-week period was estimated by intra-class correlation coefficients and ANOVA on data of a subset of patients and controls.
Results: Differences between DN subjects and both DC and C subjects were significant (P < 0.05) for all item groupings. Total quality of life (QOL) scores correlated with total neuropathy scores. The ADL, total QOL, and autonomic scores were greater in DC than C subjects (P < 0.05). Intra-class correlation coefficients were > 0.9 for most domains. Internal consistency of the fiberspecific domains using Cronbach's alpha was > 0.6 and up to 0.8.
Conclusions: The fiber-specific domains of the QOL-DN demonstrated acceptable reliability and ability to discriminate between subjects with and without neuropathy. Not surprisingly, the DN group scored significantly (P < 0.05) higher than either of the two control groups (i.e., greater impairment). The positive scores for the DC group in the ADL and autonomic domains suggest that diabetes per se impacts these aspects of QOL.
Similar articles
-
Norfolk QOL-DN: validation of a patient reported outcome measure in transthyretin familial amyloid polyneuropathy.J Peripher Nerv Syst. 2014 Jun;19(2):104-14. doi: 10.1111/jns5.12059. J Peripher Nerv Syst. 2014. PMID: 24738700
-
Quality of life and objective measures of diabetic neuropathy in a prospective placebo-controlled trial of ruboxistaurin and topiramate.J Diabetes Sci Technol. 2011 May 1;5(3):714-22. doi: 10.1177/193229681100500326. J Diabetes Sci Technol. 2011. PMID: 21722587 Free PMC article. Clinical Trial.
-
German-translated Norfolk quality of life (QOL-DN) identifies the same factors as the English version of the tool and discriminates different levels of neuropathy severity.J Diabetes Sci Technol. 2008 Nov;2(6):1075-86. doi: 10.1177/193229680800200616. J Diabetes Sci Technol. 2008. PMID: 19885296 Free PMC article.
-
The development and validation of the Cluster Headache Quality of life scale (CHQ).J Headache Pain. 2016 Dec;17(1):79. doi: 10.1186/s10194-016-0674-1. Epub 2016 Sep 5. J Headache Pain. 2016. PMID: 27596922 Free PMC article. Review.
-
Assessing the influence of actinic keratosis on patients' quality of life: the AKQoL questionnaire.Br J Dermatol. 2013 Feb;168(2):277-83. doi: 10.1111/bjd.12036. Br J Dermatol. 2013. PMID: 22962980 Review.
Cited by
-
Prediction of protective sensory loss, neuropathy and foot ulceration in type 2 diabetes.BMJ Open Diabetes Res Care. 2016 May 5;4(1):e000163. doi: 10.1136/bmjdrc-2015-000163. eCollection 2016. BMJ Open Diabetes Res Care. 2016. PMID: 27239314 Free PMC article.
-
The New Age of Sudomotor Function Testing: A Sensitive and Specific Biomarker for Diagnosis, Estimation of Severity, Monitoring Progression, and Regression in Response to Intervention.Front Endocrinol (Lausanne). 2015 Jun 11;6:94. doi: 10.3389/fendo.2015.00094. eCollection 2015. Front Endocrinol (Lausanne). 2015. PMID: 26124748 Free PMC article. Review.
-
Genotype and Phenotype of Transthyretin Cardiac Amyloidosis: THAOS (Transthyretin Amyloid Outcome Survey).J Am Coll Cardiol. 2016 Jul 12;68(2):161-72. doi: 10.1016/j.jacc.2016.03.596. J Am Coll Cardiol. 2016. PMID: 27386769 Free PMC article.
-
Effectiveness of Exposure in Vivo for Patients with Painful Diabetic Neuropathy: a Pilot Study of Effects on Physical Activity and Quality of Life.J Rehabil Med Clin Commun. 2021 Feb 10;4:1000046. doi: 10.2340/20030711-1000046. eCollection 2021. J Rehabil Med Clin Commun. 2021. PMID: 33884148 Free PMC article.
-
Activity for Diabetic Polyneuropathy (ADAPT): Study Design and Protocol for a 2-Site Randomized Controlled Trial.Phys Ther. 2017 Jan 1;97(1):20-31. doi: 10.2522/ptj.20160200. Phys Ther. 2017. PMID: 27417167 Free PMC article. Clinical Trial.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical